Hospital
Adventist Health Mendocino Coast
Adventist Health Mendocino Coast was paid $12.53M by Medicaid between Jan 2018 and Nov 2024, across 153 billing codes. Its largest line is 99283, emergency room visit (moderate) — 37% of everything it billed.
33Billing provider infoADVENTIST HEALTH MENDOCINO COAST
FORT BRAGG, CA 95437
FORT BRAGG, CA 95437
33aNPI1538113725assigned 05/20/2006
33bProvider typeCritical Access Hospital
28Total paid$12.53M
24GClaims210,765
24DCodes billed153
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in California
Rank by total paid#6 of 30
Median peer was paid$3.14M
This provider vs. median4.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,075 | $1.63M | |
| 2019 | 34,327 | $2.04M | |
| 2020 | 27,013 | $2.04M | |
| 2021 | 30,657 | $1.99M | |
| 2022 | 28,638 | $1.76M | |
| 2023 | 32,529 | $1.79M | |
| 2024incomplete | 23,526 | $1.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 37% | 26,793 | 19,900 | $4.58M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 14% | 12,456 | 10,675 | $1.77M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.2% | 8,462 | 1,662 | $526K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.3% | 3,314 | 2,958 | $413K |
| 99201 | 3.1% | 1,777 | 1,258 | $389K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 3.0% | 1,497 | 1,026 | $375K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 536 | 516 | $304K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.4% | 1,379 | 1,375 | $301K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.4% | 2,887 | 2,463 | $296K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 1,172 | 891 | $201K |
| 97139 | 1.5% | 4,372 | 852 | $184K | |
| J3490 | Unclassified drugs | 1.5% | 14,545 | 7,467 | $184K |
141 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 2,672 | $176K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 531 | $170K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 2,496 | $162K |
| 80053 | Comprehensive metabolic panel | 1.2% | 15,869 | $153K |
| 97750 | 1.1% | 1,407 | $138K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,548 | $114K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,148 | $114K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,866 | $105K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 168 | $94K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 2,489 | $94K |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 364 | $92K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,142 | $91K |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | <1% | 959 | $80K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,720 | $70K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,857 | $68K |
| 80061 | Lipid panel | <1% | 5,261 | $64K |
| 99070 | <1% | 3,013 | $63K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 327 | $46K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,687 | $44K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 723 | $43K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,171 | $41K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,905 | $39K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 771 | $39K |
| 87806 | <1% | 1,381 | $39K | |
| 85027 | <1% | 4,358 | $38K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,959 | $35K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 252 | $35K |
| 73030 | <1% | 588 | $34K | |
| 93000 | <1% | 462 | $29K | |
| A0425 | Ground mileage, per statute mile | <1% | 499 | $27K |
| 76830 | Ultrasound, transvaginal | <1% | 175 | $26K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 385 | $24K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,363 | $23K |
| 81001 | <1% | 5,342 | $23K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,332 | $23K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 29 | $20K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 406 | $20K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,708 | $19K |
| 84439 | <1% | 2,108 | $17K | |
| 87483 | <1% | 78 | $17K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 110 | $16K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 248 | $15K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,103 | $15K |
| 73610 | <1% | 274 | $15K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 98 | $15K |
| 83690 | <1% | 2,313 | $14K | |
| 84484 | <1% | 1,444 | $14K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 560 | $14K |
| 80305 | <1% | 1,078 | $14K | |
| 73630 | <1% | 233 | $13K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 252 | $12K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 803 | $12K |
| 87186 | <1% | 1,276 | $11K | |
| 83735 | <1% | 1,625 | $10K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 203 | $10K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 399 | $10K |
| 87486 | <1% | 168 | $10K | |
| 87581 | <1% | 167 | $10K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,390 | $10K |
| 85610 | <1% | 2,441 | $9K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 69 | $9K |
| 73110 | <1% | 168 | $9K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 788 | $9K |
| 73562 | <1% | 167 | $8K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 79 | $8K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 24 | $8K |
| 87070 | <1% | 872 | $8K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 26 | $8K |
| 83605 | <1% | 759 | $8K | |
| 86803 | <1% | 695 | $7K | |
| 86140 | <1% | 1,439 | $7K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 264 | $7K |
| 72141 | <1% | 13 | $7K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 548 | $7K |
| 0450 | Emergency room services | <1% | 125 | $6K |
| 83880 | <1% | 203 | $6K | |
| 81025 | <1% | 1,795 | $6K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 184 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 229 | $5K |
| 73130 | <1% | 66 | $4K | |
| 87077 | <1% | 451 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 350 | $4K |
| A4217 | Sterile water/saline, 500 ml | <1% | 78 | $4K |
| 87088 | <1% | 258 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 469 | $3K |
| 73502 | <1% | 68 | $3K | |
| 72100 | <1% | 44 | $3K | |
| 81003 | <1% | 889 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 396 | $3K |
| 82043 | <1% | 585 | $3K | |
| 82570 | <1% | 512 | $3K | |
| 86780 | <1% | 240 | $2K | |
| 86592 | <1% | 625 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 108 | $2K |
| 85652 | <1% | 907 | $2K | |
| 85730 | <1% | 350 | $2K | |
| 76642 | <1% | 12 | $2K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 74 | $2K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 30 | $1K |
| 82607 | <1% | 104 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 146 | $1K |
| Z7502 | <1% | 29 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 24 | $1K |
| 87040 | <1% | 87 | $1K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 16 | $986.40 |
| 90715 | <1% | 12 | $956.62 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 88 | $948.81 |
| 87340 | <1% | 102 | $823.84 | |
| 83550 | <1% | 106 | $796.74 | |
| 86481 | <1% | 14 | $781.48 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 113 | $660.61 |
| 73564 | <1% | 14 | $638.88 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 14 | $592.90 |
| 83540 | <1% | 119 | $584.04 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 48 | $510.62 |
| 73080 | <1% | 12 | $478.17 | |
| 80143 | <1% | 28 | $432.39 | |
| 82746 | <1% | 15 | $407.68 | |
| 86901 | <1% | 138 | $384.26 | |
| 72040 | <1% | 12 | $370.80 | |
| 82728 | <1% | 27 | $318.78 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 38 | $259.06 |
| 86850 | <1% | 95 | $252.28 | |
| 86900 | <1% | 96 | $227.21 | |
| 80179 | <1% | 12 | $178.92 | |
| 85007 | <1% | 76 | $164.92 | |
| 82784 | <1% | 14 | $164.14 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 16 | $161.68 |
| 82274 | <1% | 12 | $157.19 | |
| 84481 | <1% | 12 | $141.32 | |
| 87081 | <1% | 28 | $140.80 | |
| 84480 | <1% | 12 | $136.08 | |
| 82962 | <1% | 53 | $132.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 14 | $97.86 |
| 82550 | <1% | 14 | $60.19 | |
| 85018 | <1% | 14 | $53.82 | |
| 82248 | <1% | 13 | $52.92 | |
| 82565 | <1% | 12 | $50.40 | |
| 84156 | <1% | 14 | $33.27 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 86 | $13.71 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 13 | $0.84 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTEVENS, ERIC (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Ukiah Adventist Hospital | Ukiah, CA | $48.97M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.